These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7866205)

  • 41. Interferon beta in multiple sclerosis.
    Napier JC
    Lancet; 1999 Aug; 354(9177):512; author reply 512-3. PubMed ID: 10465197
    [No Abstract]   [Full Text] [Related]  

  • 42. Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
    Curtiss FR
    J Manag Care Pharm; 2007 Apr; 13(3):287-9. PubMed ID: 17407397
    [No Abstract]   [Full Text] [Related]  

  • 43. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A 29-year-old man with multiple sclerosis.
    Rudick RA
    JAMA; 1998 Oct; 280(16):1432-9. PubMed ID: 9801004
    [No Abstract]   [Full Text] [Related]  

  • 45. NICE and drugs for multiple sclerosis. National Institute of Clinical Excellence.
    Hartung HP
    Lancet; 2000 Sep; 356(9235):1114. PubMed ID: 11009171
    [No Abstract]   [Full Text] [Related]  

  • 46. Interferon beta-1A for relapsing multiple sclerosis.
    Med Lett Drugs Ther; 1996 Jul; 38(979):63-4. PubMed ID: 8692073
    [No Abstract]   [Full Text] [Related]  

  • 47. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glatiramer: new preparation. No place in multiple sclerosis.
    Prescrire Int; 2004 Feb; 13(69):10-2. PubMed ID: 15055208
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis.
    Hadjigeorgiou GM; Doxani C; Miligkos M; Ziakas P; Bakalos G; Papadimitriou D; Mprotsis T; Grigoriadis N; Zintzaras E
    J Clin Pharm Ther; 2013 Dec; 38(6):433-9. PubMed ID: 23957759
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies].
    Ouallet JC
    Rev Neurol (Paris); 2010 Jan; 166(1):21-31. PubMed ID: 19596382
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative studies of glatiramer acetate and interferon beta.
    Goodin D
    Int MS J; 2008 Jun; 15(2):39-41. PubMed ID: 18782497
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
    Petkau J; White R
    Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643
    [No Abstract]   [Full Text] [Related]  

  • 54. Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta1a or glatiramer acetate compared with untreated patients.
    Jansson A; Ernerudh J; Kvarnström M; Ekerfelt C; Vrethem M
    Mult Scler; 2003 Oct; 9(5):440-5. PubMed ID: 14582766
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Placebo? no thanks, it might be bad for me!
    Garattini S; Bertelé V; Banzi R
    Eur J Clin Pharmacol; 2013 Mar; 69(3):711-4. PubMed ID: 22983310
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 57. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
    Duddy M; Palace J
    Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247
    [No Abstract]   [Full Text] [Related]  

  • 58. Alemtuzumab for multiple sclerosis: who and when to treat?
    Sprenger T; Kappos L
    Lancet; 2012 Nov; 380(9856):1795-7. PubMed ID: 23128041
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New treatments and azathioprine in multiple sclerosis.
    Palace J; Rothwell P
    Lancet; 1997 Jul; 350(9073):261. PubMed ID: 9242805
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.